Threshold Pharmaceuticals, Inc.

Affymax Technologies, N.v.

Molecular Templates, Inc.

Affymax, Inc.

Charles Praray Hart

Mark D Matteucci

Peter J Schatz

Jian-Xin Duan

Antonio Gualberto

Brian A Elenbaas

Stewart Kroll

Fanying Meng

Jeffrey P Northrop

Jessica Sun

John G Curd

John Curd

Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.

Predictive biomarker for hypoxia-activated prodrug therapy

Cancer can be treated by administration of TH-302 in combination with a Chk1 inhibitor.

Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer

Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.

Treatment of cancer using hypoxia activated prodrugs

The invention provides methods for identifying agents that are ligands for nuclear receptors. The methods include conducting multiplexed assays utilizing positive hybrid systems, reverse hybrid systems, direct interaction assays and other assays to screen for ligands having activity with a receptor of interest. The methods can be performed in various multiplexing formats to produce a profile that can be used to categorize a test ligand relative to known agonists and antagonists.

Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions

A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a carrier protein fused to a random peptide through a proteolytic cleavage site can be used to identify ligands that bind to a receptor. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand, and the random peptide can easily be identified and analyzed by virtue of the carrier protein and associated proteolytic cleavage site.

Peptide library and screening method

Growing community of inventors

Mountain View, CA, United States of America

Charles Praray Hart